• EI
  • Scopus
  • 中国科技期刊卓越行动计划项目资助期刊
  • 北大核心期刊
  • DOAJ
  • EBSCO
  • 中国核心学术期刊RCCSE A+
  • 中国精品科技期刊
  • JST China
  • FSTA
  • 中国农林核心期刊
  • 中国科技核心期刊CSTPCD
  • CA
  • WJCI
  • 食品科学与工程领域高质量科技期刊分级目录第一方阵T1
中国精品科技期刊2020
王倩男,杨雯,薛婷芳,等. 人参肽对小鼠的润肠通便效果[J]. 食品工业科技,2025,46(2):1−7. doi: 10.13386/j.issn1002-0306.2024010070.
引用本文: 王倩男,杨雯,薛婷芳,等. 人参肽对小鼠的润肠通便效果[J]. 食品工业科技,2025,46(2):1−7. doi: 10.13386/j.issn1002-0306.2024010070.
WANG Qiannan, YANG Wen, XUE Tingfang, et al. Effects of Ginseng Peptides on Laxative in Mice[J]. Science and Technology of Food Industry, 2025, 46(2): 1−7. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2024010070.
Citation: WANG Qiannan, YANG Wen, XUE Tingfang, et al. Effects of Ginseng Peptides on Laxative in Mice[J]. Science and Technology of Food Industry, 2025, 46(2): 1−7. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2024010070.

人参肽对小鼠的润肠通便效果

Effects of Ginseng Peptides on Laxative in Mice

  • 摘要: 目的:研究人参肽(Ginseng peptides,GPs)对ICR小鼠便秘模型的润肠通便作用,为GPs的进一步开发利用及临床辅助治疗便秘提供理论依据。方法:将60只成年雄性ICR小鼠随机分为6组,分别为空白组(Normal Group,NG)、便秘模型组(Constipation Group,CG)、乳清蛋白组(Whey Protein Group,WPG)、低剂量(Low-dose Group,LG)、中剂量(Medium-dose Group,MG)、高剂量(High-dose Group,HG)GPs组,除NG外采用盐酸洛哌丁胺(Loperamide Hydrochloride,LH)建立小鼠便秘模型,使用GPs连续干预7 d后,观察各组小鼠的小肠蠕动及排便时间、小肠绒毛组织病理学变化等,通过检测各组小鼠的血清P物质(Substance P,SP)和血管活性肠肽(Vasoactive Intestinal Peptide,VIP)等脑肠肽类物质的含量,评价GPs对小鼠便秘的改善作用。结果:相较于模型组,GPs高、中、低剂量组小鼠小肠墨汁推进率显著增加(P<0.01),可缓解便秘小鼠小肠绒毛病理学损伤,GPs高剂量组小鼠首粒黑便排出时间显著缩短(P<0.01),粪便粒数增多(P<0.05),5 h内粪便重量显著增多(P<0.01)。GPs高、中剂量组小鼠的血清P物质(SP)和血管活性肠肽(VIP)含量显著升高(P<0.01),GPs低剂量组可升高便秘小鼠脑肠肽指标SP及VIP的含量(P<0.05)。结论:GPs对便秘小鼠模型具有明显的通便效果,可促进小肠蠕动、缓解小鼠小肠绒毛损伤,促进小鼠脑肠肽指标SP及VIP的表达。

     

    Abstract: Objective: To study the moisturizing and laxative effects of Ginseng peptides (GPs) on the constipation model of ICR mice, and provide theoretical basis for the further development and utilization of GPs and clinical adjuvant treatment of constipation. Methods: 60 adult male ICR mice were randomly divided into 6 groups, they were Normal Group (NG), Constipation Group (CG), Whey Protein Group (WPG), Low-dose GPs Group (LG), Medium-dose GPs Group (MG), High-dose GPs Group (HG). Except NG, mouse constipation model was established using Loperamide hydrochloride (LH). After 7 consecutive days of intervention with GPs, the small intestine peristalsis and defecation time, as well as pathological changes in the small intestine villus tissue of each group of mice were observed and compared. The improvement effect of GPs on mouse constipation was evaluated by detecting the content of brain gut peptide indicators in the serum of each group of mice. Results: Compared with the model group, the High, Medium, and Low dose groups of GPs significantly increased the small intestine ink advance rate in mice (P<0.01), which could alleviate the pathological damage of small intestine villi in constipated mice. Compared with the model group, the high-dose GPs group significantly shortened the first black stool excretion time (P<0.01), increased the number of fecal particles (P<0.05), and significantly increased fecal weight (P<0.01) in mice. The serum levels of substance P (SP) and vasoactive intestinal peptide (VIP) were significantly increased in the high and medium dose groups of GPs mice (P<0.01), while the low dose group of GPs increased the levels of brain intestinal peptide indicators SP and VIP in constipated mice (P<0.05). Conclusion: GPs has a significant laxative effect on a constipated mouse model, promoting small intestinal peristalsis, alleviating small intestinal villus damage, and promoting the expression of brain gut peptide markers SP and VIP in mice.

     

/

返回文章
返回